Randomized trial of the efficacy of adjuvant chemotherapy for colon cancer with combination therapy incorporating the oral pyrimidine 1-hexylcarbamoyl-5-fluorouracil
| Autor: | Yasuo Ohashi, Takashi Takahashi, Takeshi Tominaga, Susumu Kodaira, Masayuki Yasutomi, Masahiko Watanabe, Tomoyuki Kato, Kazufumi Kunitomo, Hiroharu Isomoto, Keiichi Hojo |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Oncology
medicine.medical_specialty Combination therapy Colorectal cancer Mitomycin Disease-Free Survival law.invention Randomized controlled trial law Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Stage (cooking) Aged Neoplasm Staging business.industry Liver Neoplasms Mitomycin C Combination chemotherapy Middle Aged medicine.disease Combined Modality Therapy Survival Rate Treatment Outcome Chemotherapy Adjuvant Colonic Neoplasms Toxicity Surgery Fluorouracil business Abdominal surgery |
| Zdroj: | Langenbeck's Archives of Surgery. 391:330-337 |
| ISSN: | 1435-2451 1435-2443 |
| Popis: | The purpose of the present trial was to clarify the efficacy of postoperative adjuvant chemotherapy including an oral fluoropyrimidine anticancer drug, the 1-hexylcarbamoyl-5-fluorouracil (HCFU), for the treatment of colon cancer. Patients with clinical stage Dukes’ B and C colon cancer, who had been treated surgically, were assigned to a chemotherapy group treated with mitomycin C, 5-fluorouracil (5-FU), and HCFU and to a control group that received no postoperative adjuvant chemotherapy. Of the 1,001 patients registered for the study, 17 (1.7%) were ineligible. The incidence of toxicity was significantly higher in the chemotherapy group than in the control group. However, there were few severe side effects and no deaths related to the treatment. Overall survival showed no significant difference between the groups. The disease-free survival or the recurrence-free intervals was significantly higher in the chemotherapy group than in the control group. The incidence of hepatic recurrence was significantly (P=0.003) lower in the chemotherapy group than in the control group. The results of this study demonstrated the efficacy of adjuvant chemotherapy for colon cancer, i.e., combined chemotherapy that included the 5-FU oral anticancer drug HCFU. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink